Ventripoint Appoints Head of Sales for North America
Toronto, Canada – January 10, 2018 - Ventripoint Diagnostics Ltd. (“Ventripoint” or the “Company”) (TSXV:VPT) is pleased to announce the appointment of David McPhedran as Director of Sales for North America, effective immediately.
"I am excited to welcome Dave to the Ventripoint team,” stated Desmond Hirson, President of Ventripoint. "He has a successful track record in establishing and managing sales teams for imaging products in the North American marketplace."
"I am honored and excited to join the Ventripoint team," said David McPhedran. "Ventripoint is an impressive company with innovative products to improve patient cardiac diagnosis and care. I have engaged numerous cardiologists across Canada and can report that they are very interested in Ventripoint’s technology as it helps to address the need for affordable, accurate cardiac measurement tools.”
Dave McPhedran is an experienced leader in the healthcare industry. Previously, he was Director of Sales for imaging in Western Canada for Siemens Healthcare, where his team achieved sales targets of $35M per year. Dave has also worked for Becton Dickinson and Johnson & Johnson in sales and marketing. He received his Bachelor of Science degree from the University of Waterloo.
About Ventripoint Diagnostics Ltd.
Ventripoint’s technology is a leading Artificial Intelligence (AI) approach known as Knowledge-Based Reconstruction (KBR) to create applications to monitor heart disease, a leading cause of death worldwide. The VMS+ is the first cost-effective and accurate AI tool for measuring whole heart function using conventional ultrasound. The Corporation has developed a suite of applications for all major heart diseases and is actively commercializing the approach to improve cardiac care.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this press release that are not historical facts contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint’s expectations, should be considered forward-looking statements. Such statements are based on management’s exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.